These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 27007485

  • 1. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
    Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W, Honnorat J, Vedeler CA.
    J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
    [Abstract] [Full Text] [Related]

  • 2. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
    Berger B, Bischler P, Dersch R, Hottenrott T, Rauer S, Stich O.
    J Neurol Sci; 2015 May 15; 352(1-2):58-61. PubMed ID: 25824848
    [Abstract] [Full Text] [Related]

  • 3. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
    Fu P, He L, Tang N, Nie Q, Li Z.
    J Clin Neurosci; 2021 Jul 15; 89():336-342. PubMed ID: 34119290
    [Abstract] [Full Text] [Related]

  • 4. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
    Stich O, Klages E, Bischler P, Jarius S, Rasiah C, Voltz R, Rauer S.
    Acta Neurol Scand; 2012 May 15; 125(5):326-31. PubMed ID: 21751968
    [Abstract] [Full Text] [Related]

  • 5. [Neurological syndromes, encephalitis].
    Yamamoto T, Tsuji S.
    Gan To Kagaku Ryoho; 2010 Jun 15; 37(6):995-1005. PubMed ID: 20567100
    [Abstract] [Full Text] [Related]

  • 6. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.
    Seluk L, Taliansky A, Yonath H, Gilburd B, Amital H, Shoenfeld Y, Kivity S.
    Clin Immunol; 2019 Feb 15; 199():29-36. PubMed ID: 30543927
    [Abstract] [Full Text] [Related]

  • 7. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
    Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC.
    J Neurol Neurosurg Psychiatry; 2009 Apr 15; 80(4):412-6. PubMed ID: 18931014
    [Abstract] [Full Text] [Related]

  • 8. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
    Raspotnig M, Vedeler CA, Storstein A.
    Acta Neurol Scand Suppl; 2011 Apr 15; (191):83-8. PubMed ID: 21711262
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
    Raspotnig M, Vedeler C, Storstein A.
    J Neurol Sci; 2015 Jan 15; 348(1-2):41-5. PubMed ID: 25467140
    [Abstract] [Full Text] [Related]

  • 11. Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.
    Vatankulu B, Yilmaz Aksoy S, Asa S, Sager S, Sayman HB, Halac M, Sonmezoglu K.
    Rev Esp Med Nucl Imagen Mol; 2016 Jan 15; 35(1):17-21. PubMed ID: 26260889
    [Abstract] [Full Text] [Related]

  • 12. Immunophenotypical characterization of paraneoplastic neurological syndrome patients: a multicentric study.
    Lorusso L, Precone V, Hart IK, Giometto B, Pezzani R, Ngonga GK, Ngonga GKNK, Paolacci S, Ferrari D, Ricevuti G, Marshall E, Bertelli M.
    J Biosci; 2021 Jan 15; 46():. PubMed ID: 33709965
    [Abstract] [Full Text] [Related]

  • 13. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
    Ariño H, Höftberger R, Gresa-Arribas N, Martínez-Hernández E, Armangue T, Kruer MC, Arpa J, Domingo J, Rojc B, Bataller L, Saiz A, Dalmau J, Graus F.
    JAMA Neurol; 2015 Aug 15; 72(8):874-81. PubMed ID: 26099072
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Neuropathy associated with paraneoplastic neurological syndrome].
    Mitsui Y, Kusunoki S.
    Brain Nerve; 2010 Apr 15; 62(4):387-93. PubMed ID: 20420179
    [Abstract] [Full Text] [Related]

  • 16. Multiplex serology of paraneoplastic antineuronal antibodies.
    Maat P, Brouwer E, Hulsenboom E, VanDuijn M, Schreurs MW, Hooijkaas H, Smitt PA.
    J Immunol Methods; 2013 May 31; 391(1-2):125-32. PubMed ID: 23500780
    [Abstract] [Full Text] [Related]

  • 17. Screening for anti-titin antibodies in patients with various paraneoplastic neurological syndromes.
    Berger B, Stich O, Labeit S, Rauer S.
    J Neuroimmunol; 2016 Jun 15; 295-296():18-20. PubMed ID: 27235344
    [Abstract] [Full Text] [Related]

  • 18. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects.
    Storstein A, Vedeler CA.
    Adv Clin Chem; 2007 Jun 15; 44():143-85. PubMed ID: 17682342
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Paraneoplastic neurological syndrome and autoantibodies].
    Hayashi Y, Inuzuka T.
    Brain Nerve; 2013 Apr 15; 65(4):385-93. PubMed ID: 23568986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.